MetLife Investment Management’s Keros Therapeutics KROS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $264K | Buy |
|
|||||
|
2025
Q1 | $184K | Hold |
|
|||||
|
2024
Q4 | $286K | Buy |
|
|||||
|
2024
Q3 | $991K | Hold |
|
|||||
|
2024
Q2 | $780K | Buy |
|
|||||
|
2024
Q1 | $870K | Buy |
|
|||||
|
2023
Q4 | $473K | Hold |
|
|||||
|
2023
Q3 | $379K | Hold |
|
|||||
|
2023
Q2 | $478K | Buy |
|
|||||
|
2023
Q1 | $431K | Hold |
|
|||||
|
2022
Q4 | $485K | Buy |
|
|||||
|
2022
Q3 | $318K | Hold |
|
|||||
|
2022
Q2 | $234K | Hold |
|
|||||
|
2022
Q1 | $460K | Buy |
|
|||||
|
2021
Q4 | $319K | Hold |
|
|||||
|
2021
Q3 | $216K | Hold |
|
|||||
|
2021
Q2 | $232K | Hold |
|
|||||
|
2021
Q1 | $336K | Hold |
|
|||||
|
2020
Q4 | $385K | Buy |
|
|||||
|
2020
Q3 | $147K | Hold |
|
|||||
|
2020
Q2 | $143K | Buy |
|